Single-strand conformational polymorphism (SSCP)-detected p53 gene mutations are a less sensitive marker of malignancy in pleural fluids than p53 immunostaining

Cytopathology

Volumn 10, Issue 4, 1999, Pages 259-262

  Mayall, F ^b   Cursons, R ^a   Jacobson, G ^a   Chang, B ^c  

^a UNIVERSITY OF WAIKATO   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

^c NONE

Author keywords

Carcinoma; Immunohistochemistry; p53 gene; Pleura; Single strand conformational polymorphism

Indexed keywords

DNA; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MARKER GENE; NUCLEOTIDE SEQUENCE; PLEURA CANCER; PLEURA FLUID; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BODY FLUIDS; EVALUATION STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032767312     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.1999.00182.x     Document Type: Article

References (13)

1. 1 Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992; 168: 377-81.
2. 2 Cagle PT, Brown RW, Lebovitz, RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994; 25: 443-8.
3. 3 Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, van-Marck E. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992; 168: 371-5.
4. 4 Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP. p53 as a marker of malignant disease in diagnostic cytopathology. Lancet 1991; 338: 513.
5. 5 Mayall F, Heryet A, Manga D, Kriegeskotten A. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997; 8: 9-11.
6. 6 Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? Revisited. J Pathol 1994; 172: 1-4.
7. 7 Dowell S, Derias N, Wilson PO, Lane DP, Hall PA. Expression of p53 in reactive mesothelium [letter]. Histopathology 1993; 22: 96-97.
8. 8 Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocyto-chemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54: 2914-8.
9. 9 Mayall F, Jacobson G, Wilkins R, Chang B. p53 gene mutations can be detected in the plasma of patients with large bowel carcinoma. J Clin Pathol 1998; 51: 611-3.
10. 10 Dix B, Robbins P, Careello S, House A, lacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994; 70: 585-90.
11. 11 Bosari S, Marchetti A, Buttitta F et al. Detection of p53 mutations by single-strand conformational polymorphism (SSCP) gel electrophoresis. Diagn Mol Pathol 1995; 4: 249-55.
12. 12 Carbone M, Rizzo P, Grimley PM et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997; 3: 908-12.
13. 13 Segers K, Backhovens H, Singh SK, De Voecht J, Ramael M, Van Broeckhoven C, Van Marck E. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch 1995; 427: 431-6.